B+
Bull case
25%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NVAX
NovavaxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings setup improved: management raised the 2026 revenue framework, reduced GAAP cost guidance, reported $724 million of cash, marketable securities, and restricted cash, and highlighted potentially material Sanofi milestones plus Matrix-M licensing optionality. [#8-K-2026-08-06]
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Cash, marketable securities, and restricted cash declined to $724 million from $751 million at year-end, while long-term debt was $291.5 million and stockholders' deficit was negative. [#8-K-2026-08-06]
Momentum
97
Value
44
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $11.50 · Bear $5.50Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $15.00
Why
Momentum97 · Δ7d -3.4
Value44 · Δ7d -0.1
Sentiment42 · Δ7d +14.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Cash, marketable securities, and restricted cash declined to $724 million from $751 million at year-end, while long-term debt was $291.5 million and stockholders' deficit was negative. [#8-K-2026-08-06]
- • No post-print analyst rating, estimate, or price-target revisions were available in the packet; low coverage limits confidence in the market's earnings interpretation.
- • The Q2 result still showed a $53 million net loss and a 76% year-over-year revenue decline, with the comparison distorted by prior-year one-time milestone revenue.
Catalyst clock
2026-08-06
Q2 print raised revenue framework and reduced GAAP cost guidance
Lead driver: Value · See fundamentals
Momentum
97
8% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
+0.4
Value
44
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
42
45% active weight
Current posture
7d trendImproving
Δ7d
+14.1
Δ21d
+2.5
Why this grade
Composite grade D. Momentum 96.9 / Value 43.7 / Sentiment 42.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.6B
Beta
2.58
Shares Out
164.95M
P/E (TTM)
4.0
P/S (TTM)
1.11
P/FCF (TTM) · Derived
-38.45
Rev YoY
-76.3%
EPS YoY
-152.7%
Gross Margin
+78.7%
Op Margin
-28.8%
Net Debt
-$467.91M
Current Ratio
2.33
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data